ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 653

Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol

Désirée van der Heijde1, Juergen Braun2, Martin Rudwaleit3, Oana Purcaru4 and Arthur Kavanaugh5, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3Klinikum Bielefeld, Bielefeld, Germany, 4UCB Pharma, Brussels, Belgium, 5University of California San Diego, La Jolla, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: , , ,

Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2 The impact of nr-axSpA on productivity is less well characterized. Few studies investigate associations between improvements in workplace and household productivity and symptom relief with available therapies in axSpA. Here we evaluate the association between improvements in clinical and pt-reported outcomes (PROs) and improvements in productivity in the workplace and at home in axSpA pts treated with certolizumab pegol (CZP), including AS and nr-axSpA pts.

Methods:

Associations between clinical outcomes or PROs and work and household productivity were made using Week (Wk) 24 data from the double-blind and placebo-controlled period of RAPID-axSpA (NCT01087762),3 for pts originally randomized to CZP. Clinical outcomes included achievement of ASAS40 and ASDAS Major Improvement (MI). PROs included achievement of MCID for BASFI (≥1 decrease from baseline [BL]), total back pain (≥1 decrease from BL) and ASQoL (≥2 decrease from BL). Responders and non-responders at Wk24 were compared in terms of change from BL (CFB) in workplace and household productivity, as assessed using the validated arthritis-specific Work Productivity Survey.4 Groups were compared using a non-parametric bootstrap-t method. Missing data were imputed using LOCF for WPS outcomes and NRI for clinical outcomes and PROs.

Results:

218 CZP pts entering RAPID-axSpA were included in Wk24 analyses (121 AS; 97 nr-axSpA). Pts employed at Wk24: 73.9% axSpA; 73.6% AS; 74.2% nr-axSpA. Overall, pts achieving a clinical or PRO response at Wk24 reported greater improvements in workplace and household productivity than non-responders (Table). Improvements in ASQoL and clinically meaningful reductions in functional limitation and pain were associated with improved workplace absenteeism and presenteeism. Similar results were seen in both AS and nr-axSpA pts. Numerically greater CFB was seen in nr-axSpA pts, potentially due to a slightly higher BL productivity burden in nr-axSpA vs AS.5 Responders also reported greater improvements in participation in family, social and leisure activities (not shown). Results should be interpreted with caution, due to differences in pt number between groups and because analyses were not adjusted for differences in BL productivity.

Conclusion:

Clinical responses and clinically meaningful improvements in PROs are associated with improved workplace and household productivity in axSpA pts treated with CZP, including both AS and nr-axSpA pts.

References:

  1. Boonen A. Ann Rheum Dis 2010;69:1123–8
  2. van der Heijde D. Ann Rheum Dis 2013;72:87
  3. Landewé R. Ann Rheum Dis 2014;73:39–47
  4. Osterhaus J. Arthritis Res Ther 2014;16:R164
  5. van der Heijde D. Ann Rheum Dis 2013;72:523–4

Disclosure: D. van der Heijde, AbbVie, Amgen, Astellas, AstraZeneca, BMS, Celgene, Daiichi, Eli-Lilly, Galapagos, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB Pharma, 5,Imaging Rheumatology bv, 9; J. Braun, Abbott, Bristol Myers Squibb, Celgene, Celltrion, Chugai, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB Pharma, 2,Abbott, Bristol Myers Squibb, Celgene, Celltrion, Chugai, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, UCB Pharma, 5; M. Rudwaleit, Abbott, BMS, Janssen, MSD, Pfizer, Roche, UCB Pharma, 5; O. Purcaru, UCB Pharma, 3; A. Kavanaugh, Abbott, Amgen, BMS, Pfizer, Roche, Janssen, UCB Pharma, 2.

To cite this abstract in AMA style:

van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-responses-and-improvements-in-patient-reported-outcomes-are-associated-with-increased-productivity-in-the-workplace-and-at-home-in-axial-spondyloarthritis-patients-treated-with-certolizumab-p/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-responses-and-improvements-in-patient-reported-outcomes-are-associated-with-increased-productivity-in-the-workplace-and-at-home-in-axial-spondyloarthritis-patients-treated-with-certolizumab-p/